Novella M, Solà R, Soriano G, Andreu M, Gana J, Ortiz J, Coll S, Sàbat M, Vila M C, Guarner C, Vilardell F
Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Hepatology. 1997 Mar;25(3):532-6. doi: 10.1002/hep.510250306.
Cirrhotic patients with ascites and low ascitic fluid total protein and/or high serum bilirubin levels are at high risk to develop the first episode of spontaneous bacterial peritonitis during long-term follow-up. The aim of the present study was to determine the efficacy of continuous long-term selective intestinal decontamination with norfloxacin in the prevention of this complication. One hundred nine cirrhotic patients with ascites and ascitic fluid total protein levels of < or = 1 g/dL or serum bilirubin levels of > 2.5 mg/dL without previous spontaneous bacterial peritonitis were prospectively randomized into two groups: group 1 (n = 56) received norfloxacin, 400 mg daily administered orally, and group 2 (n = 53) was the long-term control group, receiving norfloxacin only during hospitalization. During a mean follow-up of 43 +/- 3 weeks, there was one spontaneous bacterial peritonitis (1.8%) in group 1 and 9 (16.9%) in group 2 (P < .01). The incidence of community-acquired spontaneous bacterial peritonitis was lower in group 1 (1.8% vs. 13.2%, P < .05), whereas the incidence of nosocomial spontaneous bacterial peritonitis (0% vs. 3.7%) and the incidence of extraperitoneal infections (25% vs. 24.5%) were similar in both groups (P = NS). The actuarial probability of survival at 18 months was 75% in group 1 and 62% in group 2 (P = NS). Resistance to norfloxacin was observed in 9 of 10 (90%) Escherichia coli isolated in infections from group 1 and in 4 of 11 (36.3%) from group 2 (P < .05). The overall incidence of infections caused by norfloxacin-resistant bacteria was higher in group 1 (19.6% vs. 15%), but it did not reach statistical significance. Continuous long-term selective intestinal decontamination with norfloxacin is effective in preventing the first spontaneous bacterial peritonitis in cirrhotic patients at high risk. However, the emergence of infections caused by norfloxacin-resistant bacteria must be weighed carefully against the benefits of continuous long-term prophylaxis.
腹水且腹水总蛋白低和/或血清胆红素水平高的肝硬化患者在长期随访期间发生首次自发性细菌性腹膜炎的风险很高。本研究的目的是确定长期连续使用诺氟沙星进行选择性肠道去污在预防该并发症方面的疗效。109例腹水且腹水总蛋白水平≤1g/dL或血清胆红素水平>2.5mg/dL且既往无自发性细菌性腹膜炎的肝硬化患者被前瞻性随机分为两组:第1组(n = 56)口服诺氟沙星,每日400mg,第2组(n = 53)为长期对照组,仅在住院期间接受诺氟沙星治疗。在平均43±3周的随访期间,第1组有1例自发性细菌性腹膜炎(1.8%),第2组有9例(16.9%)(P<0.01)。第1组社区获得性自发性细菌性腹膜炎的发生率较低(1.8%对13.2%,P<0.05),而两组医院获得性自发性细菌性腹膜炎的发生率(0%对3.7%)和腹膜外感染的发生率(25%对24.5%)相似(P=无显著性差异)。第1组18个月时的精算生存率为75%,第2组为62%(P=无显著性差异)。在第1组感染中分离出的10株大肠杆菌中有9株(90%)对诺氟沙星耐药,第2组11株中有4株(36.3%)对诺氟沙星耐药(P<0.05)。第1组由耐诺氟沙星细菌引起的感染总发生率较高(19.6%对15%),但未达到统计学显著性。长期连续使用诺氟沙星进行选择性肠道去污可有效预防高危肝硬化患者的首次自发性细菌性腹膜炎。然而,耐诺氟沙星细菌引起的感染的出现必须与长期连续预防的益处仔细权衡。